Genprex announces positive preclinical data for Reqorsa at AACR 2026

Genprex, Inc.

TROP2 and PTEN identified as potential biomarkers of primary resistance to TUSC2 gene therapy; 50% of NSCLC cell lines resistant.
Reqorsa plus alectinib achieved 79% tumor shrinkage in ALK+ sensitive model, 23% improvement vs alectinib alone.
In alectinib-resistant model, Reqorsa + alectinib produced synergistic tumor reduction and improved overall survival (p=0.0001).
TUSC2 restoration enhanced NK cell cytotoxicity; 67% of Tusc2 KO mice and 33% of wild-type mice achieved complete tumor regression.
Findings support progression toward clinical trials for ALK+ NSCLC and biomarker-guided patient selection.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.